Pfizer reported FY 2025 total revenues of USD 62.6 billion, down 2.0% from FY 2024, with net cash flow from operations of USD 11.7 billion, down 8.0%. FY 2025 net income attributable to common shareholders was USD 7.8 billion, with reported diluted EPS of USD 1.36, down 3.0%, and adjusted diluted EPS (non-GAAP) of USD 3.22, up 4.0%. FY 2025 cost of sales was USD 16.1 billion (25.7% of total revenues), while selling, informational and administrative expenses were USD 13.8 billion and R&D expenses were USD 10.4 billion. COVID-19 products continued to decline, with FY 2025 Comirnaty revenue of USD 4.4 billion, down 20.0%, and Paxlovid revenue of USD 2.4 billion, down 59.0%. Growth drivers cited in FY 2025 included the Vyndaqel family (USD 6.4 billion, up 16.0%), Eliquis (USD 8.0 billion, up 7.0%), Padcev (USD 1.9 billion, up 22.0%), Lorbrena (USD 1.0 billion, up 40.0%) and Abrysvo (USD 1.0 billion, up 36.0%). Pfizer said the Inflation Reduction Act’s Medicare Part D redesign negatively impacted FY 2025 revenues by about USD 1.0 billion, and noted Eliquis’ Medicare drug price negotiation Maximum Fair Price became effective January 1, 2026. On strategy and corporate updates, Pfizer highlighted progress on its multi-year cost realignment program, targeting total net cost savings of about USD 5.7 billion through 2026 (USD 5.1 billion achieved through FY 2025), and said it expects about USD 1.0 billion of annual cost synergies from the Seagen acquisition by end-2026 (about USD 800 million achieved by year-end 2025). The company also reported paying USD 6.9 billion for the acquisition of Metsera (net of cash acquired) in FY 2025 and disclosed a September 2025 agreement with the U.S. government to implement measures to make certain U.S. drug prices more comparable to other developed countries, alongside a three-year grace period from Section 232 tariffs tied to further U.S. manufacturing investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000078003-26-000026), on February 26, 2026, and is solely responsible for the information contained therein.